Shares of famous Danish weight-drug loss producer Novo Nordisk (NOVOB.DK) are reaching now all-time highs above 1000 DKK as Wegovy weight-loss treatment received approval from regulators in China.
- Novo Nordisk didn't comment when exactly it will be selling its products on Chinese market. Supply nor Wegovy prices on Chinese market are not known. According to a Chinese public health study, number of overweight adults in China can reach 540 million by 2030 rising 280% since 2000 level.
- Novo Nordisk is currently the highest valued, European company and year-to-date Novo risen almost 45%. Yesterday, on Monday 24 June, the company announced $4.1 facility investment in the North Carolina (US), to boost its manufacturing capabilities.
Novo Nordisk (NOVOB.DK, D1 interval)
During last 12 months the most important support zone for Novo Nordisk was near SMA50 (orange line) and in correction scenario levels near 900-920DKK may be important.
Source: xStation5
Morning Wrap: ตลาดจะฟื้นตัวได้หรือไม่ หลังเกิดข่าวฉาวที่นำไปสู่การพ้นตำแหน่งของ CEO Nvidia? ❓
Nvidia เสียผู้ก่อตั้ง แต่ AI ไม่ได้เสียความเชื่อมั่น ตัวที่กดตลาดจริงคือดอกเบี้ย
📉 Nvidia ร่วง 10% หลัง Jensen Huang ลาออก
🚨 US100 ใกล้ทะลุแนวต้านสำคัญแล้ว!